Esperion
Cardiometabolic Therapeutics · Prescription Drugs

Esperion revenue, results and funding

Esperion filed revenue of $403.1M for 2025.

Data updated Nov 22, 2026 · Back to the company report
$403.1MRevenue, 2025
−$22.7MNet income, 2025

Results by year

YearRevenueNet incomeTotal assetsLANG_CR_S_M_TAX_PAIDLANG_CR_S_M_TAX_EXPENSELANG_CR_S_M_BUYBACKSLANG_CR_S_M_CAPEXLANG_CR_S_M_SBCLANG_CR_S_M_RNDLANG_CR_S_M_OPERATING_INCOMELANG_CR_S_M_CASHLANG_CR_S_M_DEBT
2025$403.1M−$22.7M$465.9M$612k$1.8M–$0$9.9M$47.9M$60.3M$167.9M–
2024$332.3M−$51.7M$343.8M$0$0–$317k$12M$46.2M$54.4M$144.8M–
2023$116.3M−$209.2M$205.8M$0$0–$0$12M$86.1M−$155.6M$82.2M–
2022$75.5M−$233.7M$247.9M–$0–$0$15.2M$118.9M−$179.5M$124.8M–
2021$78.4M−$269.1M$381.6M–$0$0$0$24.3M$106M−$226.7M$208.9M–
2020$227.5M−$143.6M$353.3M–$0$55M$869k$28.4M$146.9M−$121.4M$305M–
2019$148.4M−$97.2M$214.4M–$0$0$953k$25.9M$175.6M−$93.1M$166.1M–
2018$0−$201.8M$143.5M–$0$0$151k$24M$171.5M−$204.6M$37M–
2017–−$167M$277.8M–$0–$19k$18.6M$147.6M−$169M$34.5M–
2016–−$75M$245.2M–$0–$94k$16M$57.9M−$76.2M$38.2M$1M
2015–−$49.8M$295.6M–$0–$325k$12.7M$29.8M−$50M$77.3M$2.7M
2014–−$36.4M$143.3M–$0–$873k$3.7M$25.3M−$36.2M$85M$4.2M
2013–−$26.1M$78.3M–$0–$31k$1.2M$16M−$22.8M$56.5M–
2012–−$11.7M$7.3M–$0–$7k$80k$8M−$10.2M$6.5M$7.5M
2011–−$10.8M––$0–$34k$78k$7.8M−$10.2M$1.6M–
Sources: SEC

How to cite

Esperion, Financials. Alion, Nov 22, 2026. https://alion.io/company/esperion/financials

.json · .md · CC BY-SA 4.0